BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37358603)

  • 21. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraductal papillary-mucinous adenocarcinoma in the remnant pancreas after pancreatoduodenectomy for cancer of Vater's papilla associated with intraductal papillary-mucinous adenoma.
    Ishida M; Egawa S; Sakata N; Mikami Y; Motoi F; Abe T; Fukuyama S; Sunamura M; Furukawa T; Unno M
    J Hepatobiliary Pancreat Surg; 2007; 14(5):522-5. PubMed ID: 17909725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraductal papillary mucinous neoplasms with associated invasive carcinoma of the pancreas: imaging findings and diagnostic performance of MDCT for prediction of prognostic factors.
    Kim JH; Eun HW; Kim KW; Lee JY; Lee JM; Han JK; Choi BI
    AJR Am J Roentgenol; 2013 Sep; 201(3):565-72. PubMed ID: 23971447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mural nodule in branch duct-type intraductal papillary mucinous neoplasms of the pancreas is a marker of malignant transformation and indication for surgery.
    Akita H; Takeda Y; Hoshino H; Wada H; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Mori M; Doki Y; Nagano H
    Am J Surg; 2011 Aug; 202(2):214-9. PubMed ID: 21376305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Neutrophil-to-Lymphocyte Ratio Predicts Malignant Potential in Intraductal Papillary Mucinous Neoplasms.
    Arima K; Okabe H; Hashimoto D; Chikamoto A; Kuroki H; Taki K; Kaida T; Higashi T; Nitta H; Komohara Y; Beppu T; Takeya M; Baba H
    J Gastrointest Surg; 2015 Dec; 19(12):2171-7. PubMed ID: 26443528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review of the utility of 18-FDG PET in the preoperative evaluation of IPMNs and cystic lesions of the pancreas.
    Srinivasan N; Koh YX; Goh BKP
    Surgery; 2019 May; 165(5):929-937. PubMed ID: 30577952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraductal oncocytic papillary neoplasm (IOPN): two case reports and review of the literature.
    Innocenti L; Rotondo MI; Donati F; Boggi U; Campani D
    Transl Cancer Res; 2023 Mar; 12(3):663-672. PubMed ID: 37033351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm.
    Fujita Y; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Ueno M; Hayami S; Kobayashi R; Yanagisawa A; Yamaue H
    Eur J Surg Oncol; 2022 May; 48(5):1054-1061. PubMed ID: 34933794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas.
    Basturk O; Chung SM; Hruban RH; Adsay NV; Askan G; Iacobuzio-Donahue C; Balci S; Zee SY; Memis B; Shia J; Klimstra DS
    Virchows Arch; 2016 Nov; 469(5):523-532. PubMed ID: 27591765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Branch-duct intraductal papillary mucinous neoplasm (IPMN): Are cyst volumetry and other novel imaging features able to improve malignancy prediction compared to well-established resection criteria?
    Pozzi Mucelli RM; Moro CF; Del Chiaro M; Valente R; Blomqvist L; Papanikolaou N; Löhr JM; Kartalis N
    Eur Radiol; 2022 Aug; 32(8):5144-5155. PubMed ID: 35275259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-invasive intraductal oncocytic papillary neoplasm forming a protruding lesion toward the duodenum from the accessory papilla: a case report.
    Kawahara S; Yamamoto N; Washimi K; Kanemoto R; Takahashi D; Kamioka Y; Hashimoto I; Kamiya M; Kato A; Maezawa Y; Kazama K; Murakawa M; Sawazaki S; Aoyama T; Tamagawa H; Oshima T; Yukawa N; Rino Y; Yokose T; Saito A; Morinaga S
    Surg Case Rep; 2024 Feb; 10(1):43. PubMed ID: 38358457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.
    Nara S; Onaya H; Hiraoka N; Shimada K; Sano T; Sakamoto Y; Esaki M; Kosuge T
    Pancreas; 2009 Jan; 38(1):8-16. PubMed ID: 18665010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraductal oncocytic papillary neoplasm of the pancreas with strong accumulation on FDG-PET.
    Kato Y; Nakagouri T; Konishi M; Takahashi S; Gotoda N; Hasebe T; Kinosita T
    Hepatogastroenterology; 2008; 55(84):900-2. PubMed ID: 18705293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression.
    Roch AM; Ceppa EP; Al-Haddad MA; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Ann Surg; 2014 Oct; 260(4):680-8; discussion 688-90. PubMed ID: 25203885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-operative nomogram predicting malignant potential in the patients with intraductal papillary mucinous neoplasm of the pancreas: focused on imaging features based on revised international guideline.
    Hwang JA; Choi SY; Lee JE; Kim SS; Lee S; Moon JY; Heo NH
    Eur Radiol; 2020 Jul; 30(7):3711-3722. PubMed ID: 32095876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
    Hirono S; Tani M; Kawai M; Ina S; Nishioka R; Miyazawa M; Fujita Y; Uchiyama K; Yamaue H
    Arch Surg; 2009 Apr; 144(4):345-9; discussion 349-50. PubMed ID: 19380648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas.
    Fritz S; Hackert T; Hinz U; Hartwig W; Büchler MW; Werner J
    Br J Surg; 2011 Jan; 98(1):104-10. PubMed ID: 20949535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
    Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
    Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Threshold of Main Pancreatic Duct Diameter in Identifying Malignant Intraductal Papillary Mucinous Neoplasm by Magnetic Resonance Imaging.
    Zhang H; Cao Y; Ren S; Guo K; Zhang Y; Lin T; Wang Y; Chen X; Wang Z
    Technol Cancer Res Treat; 2023; 22():15330338231170942. PubMed ID: 37078135
    [No Abstract]   [Full Text] [Related]  

  • 40. Decision making for pancreatic resection in patients with intraductal papillary mucinous neoplasms.
    Xu B; Ding WX; Jin DY; Wang DS; Lou WH
    World J Gastroenterol; 2013 Mar; 19(9):1451-7. PubMed ID: 23539521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.